XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Dec. 16, 2022
Cover [Abstract]  
Amendment Flag true
Entity Central Index Key 0001806310
Document Type 8-K/A
Document Period End Date Dec. 16, 2022
Entity Registrant Name Taysha Gene Therapies, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39536
Entity Tax Identification Number 84-3199512
Entity Address, Address Line One 3000 Pegasus Park Drive
Entity Address, Address Line Two Suite 1430
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75247
City Area Code (214)
Local Phone Number 612-0000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.00001 par value
Trading Symbol TSHA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Description On December 22, 2022, Taysha Gene Therapies, Inc. (the “Company”) filed a Form 8-K (the “Original Form 8-K”) reporting under Item 5.02 the resignation of R.A. Session II as the Company’s President and Chief Executive Officer and the appointment of each of Sean Nolan as Chief Executive Officer and Sukumar Nagendran, M.D. as President and Head of Research and Development. Compensation arrangements and terms of service for Mr. Nolan and Dr. Nagendran had not been determined as of the filing of the Original Form 8-K. This Current Report on Form 8-K/A is being filed solely for the purpose of amending the Original Form 8-K to provide brief descriptions of (i) the employment agreement entered into with Mr. Nolan, effective as of December 30, 2022 (the “Nolan Employment Agreement”), in connection with his appointment as Chief Executive Officer and (ii) the employment agreement entered into with Dr. Nagendran, effective as of December 30, 2022 (the “Nagendran Employment Agreement), in connection with his appointment as President and Head of Research and Development. Except as expressly set forth herein, this Current Report on Form 8-K/A does not amend, modify or update the disclosures contained in the Original Form 8-K.